Baricitinib (LY3009104) is a potent, selective, and reversible JAK1/2 inhibitor. It affects the JAK/STAT signaling pathway by inhibiting JAK kinase activity and preventing STAT phosphorylation, effectively suppressing inflammation, immune cell activation, fibrosis, and viral infectivity.
Baricitinib (LY3009104) IC50 for Cell-based and Cell-free Assays
Comprehensive IC50 Values for Baricitinib (LY3009104) Across Cell-free Enzyme Inhibitory Profiles and Cell-based Functional Assays.